MPM BIOIMPACT LLC
Reported holdings as of Q2 2026, from 27 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| CULLINAN THERAPEUTICS INC | CGEM | $177.2M | 9,731,341 | +2.41pp | 22q | +27.2%+$37.9M | |
| AKTIS ONCOLOGY INC | AKTS | $155.9M | 4,835,872 | +2.82pp | 2q | HELD | |
| LIQUIDIA CORPORATION | LQDA | $110.5M | 1,386,174 | +2.64pp | 4q | -1.4%-$1.5M | |
| REVOLUTION MEDICINES INC | RVMD | $92.2M | 492,483 | +1.82pp | 20q | -2.8%-$2.7M | |
| CORCEPT THERAPEUTICS INC | CORT | $67.0M | 771,028 | +1.02pp | 2q | -21.8%-$18.7M | |
| EDGEWISE THERAPEUTICS INC | EWTX | $65.9M | 1,620,780 | -0.02pp | 10q | -2.4%-$1.6M | |
| TRAVERE THERAPEUTICS INC | TVTX | $63.8M | 1,122,731 | +1.29pp | 2q | -0.9%-$604.1K | |
| DBV TECHNOLOGIES S A | DBVT | $60.1M | 3,666,284 | -4.74pp | 5q | -29.7%-$25.4M | |
| TREVI THERAPEUTICS INC | TRVI | $57.3M | 3,073,577 | +0.46pp | 10q | -6.8%-$4.2M | |
| ALUMIS INC | ALMS | $56.8M | 2,019,020 | -0.60pp | 3q | -15.4%-$10.3M | |
| UNIQURE NV | QURE | $56.5M | 1,225,855 | +1.71pp | 3q | -10.5%-$6.6M | |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | $47.4M | 1,418,215 | - | new | NEW | |
| RELAY THERAPEUTICS INC | RLAY | $45.2M | 2,415,672 | +0.94pp | 14q | +2.4%+$1.0M | |
| ABIVAX SA | ABVX | $44.8M | 336,347 | +1.81pp | 3q | +213.6%+$30.5M | |
| DYNE THERAPEUTICS INC | DYN | $42.7M | 1,922,093 | +0.63pp | 5q | +36.5%+$11.4M | |
| DIANTHUS THERAPEUTICS INC | DNTH | $40.9M | 420,002 | -0.25pp | 2q | -0.9%-$388.0K | |
| BIOAGE LABS INC | BIOA | $40.9M | 1,667,661 | - | new | NEW | |
| UROGEN PHARMA LTD | URGN | $34.3M | 933,415 | +0.78pp | 4q | -1.1%-$382.3K | |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | $31.3M | 1,606,967 | -0.70pp | 2q | -11.3%-$4.0M | |
| PALVELLA THERAPEUTICS INC NE | PVLA | $31.2M | 204,027 | -0.09pp | 4q | -1.2%-$363.3K | |
| TAYSHA GENE THERAPIES INC | TSHA | $30.6M | 4,500,000 | - | new | NEW | |
| SYNDAX PHARMACEUTICALS INC | SNDX | $29.2M | 1,333,523 | -0.64pp | 4q | -0.5%-$157.6K | |
| MONTE ROSA THERAPEUTICS INC | GLUE | $28.1M | 1,161,081 | +0.22pp | 3q | -1.3%-$383.5K | |
| ZURA BIO LTD | ZURA | $26.4M | 4,472,843 | - | new | NEW | |
| NATERA INC | NTRA | $25.1M | 92,638 | +0.10pp | 10q | HELD | |
| STOKE THERAPEUTICS INC | STOK | $23.7M | 723,314 | -0.49pp | 8q | -5.7%-$1.4M | |
| ADLAI NORTYE LTD | ANL | $22.3M | 1,936,291 | - | new | NEW | |
| BELITE BIO INC | BLTE | $21.1M | 137,208 | +0.20pp | 3q | +55.8%+$7.6M | |
| FORTE BIOSCIENCES INC | FBRX | $21.0M | 987,448 | -0.72pp | 2q | -1.3%-$281.2K | |
| ORIC PHARMACEUTICALS INC | ORIC | $20.4M | 1,882,162 | -0.52pp | 6q | +4.3%+$847.1K | |
| TARSUS PHARMACEUTICALS INC | TARS | $20.3M | 322,007 | -0.55pp | 5q | -2.3%-$487.3K | |
| ANNEXON INC | ANNX | $20.2M | 3,544,354 | - | new | NEW | |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | $14.2M | 202,114 | -0.33pp | 3q | -4.7%-$706.3K | |
| ENTRADA THERAPEUTICS INC | TRDA | $9.2M | 1,253,053 | - | new | NEW | |
| ACLARIS THERAPEUTICS INC | ACRS | $5.5M | 1,042,467 | +0.22pp | 2q | +166.0%+$3.4M | |
| CONTEXT THERAPEUTICS INC | CNTX | $719.5K | 1,299,046 | -2.12pp | 7q | -87.8%-$5.2M | |
| WEREWOLF THERAPEUTICS INC | HOWL | $28.9K | 80,142 | -0.08pp | 21q | -93.4%-$406.3K |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $1.6B | 98.5% |
| Healthcare Services | $25.1M | 1.5% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $1.6B | 37 | 7 | 7 | 21 | 11 | 55.3% | 45 |
| Q1 2026 | $1.3B | 41 | 11 | 6 | 7 | 8 | 49.0% | 45 |
| Q4 2025 | $874.0M | 38 | 15 | 6 | 16 | 17 | 49.8% | 48 |
| Q3 2025 | $610.9M | 40 | 7 | 3 | 2 | 11 | 48.8% | 45 |
| Q2 2025 | $577.2M | 44 | 8 | 10 | 15 | 7 | 45.3% | 45 |
| Q1 2025 | $581.7M | 43 | 6 | 25 | 8 | 10 | 47.6% | 45 |
| Q4 2024 | $704.4M | 47 | 11 | 21 | 11 | 7 | 44.7% | 45 |
| Q3 2024 | $666.6M | 43 | 10 | 18 | 6 | 11 | 55.8% | 44 |
| Q2 2024 | $643.5M | 44 | 10 | 24 | 4 | 4 | 53.5% | 45 |
| Q1 2024 | $622.0M | 38 | 12 | 10 | 3 | 6 | 55.5% | 45 |
| Q4 2023 | $427.4M | 32 | 2 | 1 | 8 | 2 | 60.7% | 44 |
| Q3 2023 | $374.6M | 32 | 5 | 7 | 1 | 7 | 61.5% | 45 |
| Q2 2023 | $496.6M | 34 | 10 | 17 | 1 | 7 | 64.9% | 45 |
| Q1 2023 | $384.9M | 31 | 1 | 10 | 11 | 3 | 70.3% | 42 |
| Q4 2022 | $385.5M | 33 | 5 | 15 | 4 | 10 | 72.8% | 45 |
| Q3 2022 | $422.2M | 38 | 4 | 4 | 12 | 3 | 68.7% | 45 |
| Q2 2022 | $360.0M | 37 | 4 | 3 | 1 | 4 | 69.7% | 42 |
| Q1 2022 | $372.6M | 37 | 5 | 4 | 17 | 1 | 67.4% | 43 |
| Q4 2021 | $548.5M | 33 | 2 | 2 | 21 | 2 | 73.1% | 42 |
| Q3 2021 | $644.7M | 33 | 19 | 7 | 3 | 0 | 72.4% | 46 |
| Q2 2021 | $608.7M | 14 | 1 | 0 | 4 | 0 | 91.9% | 44 |
| Q1 2021 | $795.9M | 13 | 1 | 0 | 5 | 4 | 96.2% | 43 |
| Q4 2020 | $588.5M | 16 | 4 | 0 | 0 | 0 | 92.7% | 47 |
| Q3 2020 | $415.1M | 12 | 1 | 1 | 0 | 0 | 97.9% | 50 |
| Q2 2020 | $376.1M | 11 | 3 | 1 | 0 | 2 | 99.8% | 43 |
| Q1 2020 | $163.7M | 10 | 1 | 0 | 0 | 3 | 100.0% | 43 |
| Q4 2019 | $282.2M | 12 | 0 | 0 | 0 | 0 | 99.5% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.